24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:12
Israeli credit card spending hit record $36 billion this summer
17:27
Netherlands turns to Elbit to take its counter-drone system from soft kill to hard kill
16:15
Swiss Re further scales back its management presence in Israel
15:18
XTEND’s 25% surge in debut gives Israeli drone maker a strong start on Wall Street
More stories
Buzz
Most popular
Daily
Weekly
1
Wonderful is growing like Wiz, but its business is very different
2
U.S. airlines return to Israel as foreign carriers rebuild flight capacity
3
ServiceNow acquires Israeli AI startup Sweep in deal estimated at hundreds of millions
4
Hapag-Lloyd and FIMI to submit improved bid for Zim
5
Israel’s academic isolation is becoming harder to ignore
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen